Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.

[1]  I. Barr,et al.  Burden of influenza B virus infection and considerations for clinical management. , 2020, Antiviral research.

[2]  Steven M. Lemieux,et al.  Clinical outcomes of baloxavir versus oseltamivir in patients hospitalized with influenza A. , 2020, The Journal of antimicrobial chemotherapy.

[3]  M. Ison,et al.  A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination With Oseltamivir in Elderly and Nonelderly Adults Hospitalized With Influenza A Infection: OPAL Study , 2020, The Journal of infectious diseases.

[4]  D. Hui,et al.  Development of an Ordinal Scale Treatment Endpoint for Adults Hospitalized With Influenza. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  F. Hayden,et al.  Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. , 2020, The Lancet. Infectious diseases.

[6]  P. Piedra,et al.  Baloxavir Marboxil Single-dose Treatment in Influenza-infected Children , 2020, The Pediatric infectious disease journal.

[7]  V. Cosson,et al.  Population Pharmacokinetics and Exposure-Response Relationships of Baloxavir Marboxil in Influenza Patients at High Risk of Complications , 2020, Antimicrobial Agents and Chemotherapy.

[8]  N. Tachikawa,et al.  Early combination treatment with baloxavir and peramivir for hospitalized adults with influenza A in Yokohama, Japan , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  H. Goossens,et al.  Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial , 2019, The Lancet.

[10]  Naoko Higuchi,et al.  Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection , 2018, The Journal of antimicrobial chemotherapy.

[11]  R. Finberg,et al.  Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial , 2018, The Journal of infectious diseases.

[12]  T. File,et al.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  F. Hayden,et al.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents , 2018, The New England journal of medicine.

[14]  P. Schreckenberger,et al.  Multicenter Evaluation of BioFire FilmArray Respiratory Panel 2 for Detection of Viruses and Bacteria in Nasopharyngeal Swab Samples , 2018, Journal of Clinical Microbiology.

[15]  A. Monto,et al.  Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study , 2018, Influenza and other respiratory viruses.

[16]  P. Yates,et al.  Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. , 2017, The Lancet. Respiratory medicine.

[17]  S. Pocock,et al.  Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials , 2015, The Lancet.

[18]  A. Monto,et al.  Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Gokhan Metan,et al.  Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. , 2014, The Lancet. Respiratory medicine.

[20]  A. Osterhaus,et al.  Detection of Nonhemagglutinating Influenza A(H3) Viruses by Enzyme-Linked Immunosorbent Assay in Quantitative Influenza Virus Culture , 2014, Journal of Clinical Microbiology.

[21]  D. Hui,et al.  A Clinical Trial of Intravenous Peramivir Compared with Oral Oseltamivir for the Treatment of Seasonal Influenza in Hospitalized Adults , 2013, Antiviral therapy.

[22]  Thi Tham Nguyen.  Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial , 2013, BMJ.

[23]  Robert Schechter,et al.  Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Ison,et al.  Diagnosis, management and outcomes of adults hospitalized with influenza. , 2012, Antiviral therapy.

[25]  F. Hayden,et al.  End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. , 2010, The Journal of infectious diseases.

[26]  D. Hui,et al.  Clinical Management of Pandemic 2009 Influenza A(H1N1) Infection , 2010, Chest.

[27]  W G Alvord,et al.  Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. , 1999, The Journal of infectious diseases.